Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Bother Control Administrations for 2024: Decide for Your Home - 2The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- 3Bavarian leader questions Germany's Eurovision participation
- 4Dominating the Remote Work Way of life: Individual Systems
- 5What are the health benefits of whole milk for kids?
- The Best Computer games Ever
- Artemis II astronauts will see parts of the moon no human has before. Here’s how
- Auschwitz Committee wants German auction of Holocaust items scrapped
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- Figure out How to Alter Your Volvo XC40 for Further developed Solace
- The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown?
- What to know about MIT professor Nuno Loureiro and the investigation into his shooting
